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Although continuous positive airway pressure (CPAP) is the most effective therapy for
obstructive sleep apnea (OSA), it is not always well tolerated by the patients. Previous
physiological studies showed that pressure oscillations applied to the pharynx could
activate upper airway muscles, but it is not clear whether these pressure oscillations
could be tolerated during sleep in OSA patients. The aim of this study was to assess
the tolerance of oscillating positive airway pressure (O-PAP) (a CPAP device delivering
high-frequency pressure oscillations to the upper airway) compared to CPAP. Fourteen
OSA patients currently on CPAP [age 59.910.1 years old, BMI 34.87.2 kg/m2,
initial apnea–hypopnea index (AHI): 58.725.2 events/h] used O-PAP or CPAP on two
consecutive nights under polysomnography, in a single-blind randomized crossover
design to assess sleep quality. A subtherapeutic pressure (70% of the optimal titrated
pressure) was applied in both conditions and the residual AHI with each technique was
also compared. There was no difference in measured or perceived sleep quality between
the two treatment modalities (sleep efficiency 90.0% versus 88.1%, p=0.54). Despite
the small sample, we also found a trend toward a decrease in residual respiratory events
with O-PAP compared to CPAP (median AHI 14.3 versus 20.5/h, p=0.194). The good
tolerance of O-PAP and the positive trend toward a reduction in residual AHI should
stimulate further research on the effects of O-PAP in OSA patients.
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Introduction
Obstructive sleep apnea (OSA) syndrome is caused by repetitive closure of the pharynx during sleep.
Although continuous positive airway pressure (CPAP) has been accepted as the standard treatment
for moderate to severe OSA (1), many patients report discomfort or cannot tolerate it. Some of the
common side effects such as air leaks,mask discomfort, or aerophagia are related to the pressure level
applied (2). Therefore, anymeans allowing a reduction of the pressure level without jeopardizing the
primary CPAP function might improve patients’ comfort and, possibly, treatment adherence.
The collapse of the upper airway in OSA is mainly due to a failure of the pharyngeal
dilator muscles to counteract the negative intraluminal pressure generated by the inspiratory
muscles. During wakefulness, the pharynx is kept opened by tonic and phasic activations of
the dilator muscles during the breathing cycle. These muscles are also activated by a reflex
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(the “pharyngeal dilators reflex”) triggered by mechanoreceptors
located in the pharynx and larynx, responding to intraluminal
negative pressure. In OSA patients, many abnormalities have been
described in the neuromuscular control of the upper airway,
including histological evidence of denervation, decreased sensi-
tivity to vibrations and temperature, and EMG evidence of motor
neuropathy (3).
Therefore, dilator muscles are an interesting target in OSA
treatment and studies investigating oropharyngeal muscle train-
ing by exercises (4), or direct stimulation (5–7), have shown a
positive impact on respiratory events.
In an animal study, Plowman et al. demonstrated that high-
frequency–low-pressure oscillations delivered to the upper airway
of dogs could trigger an augmentation of the genioglossus (GG)
electromyographic activity, both duringwakefulness and sleep (8).
In a human physiological study, Henke and Sullivan showed that
intermittent high-frequency–low-amplitude pressure oscillations
also had a stimulating effect on the upper airway muscle tone
(9). When applied to single breaths in sleeping subjects, this
oscillating pressure induced a significant activation of the GG
muscle and an increase in tidal volume in controls and OSA
patients.
Based on these physiological studies, an experimental device
was developed (the oscillating positive airway pressure, or “O-
PAP”) to deliver pressure oscillations superimposed onto CPAP
therapy. As it was unclear whether these pressure oscillations
could be tolerated during sleep, we designed this study to assess
sleep quality under O-PAP, compared to CPAP.
Subjects and Methods
Participants
Subjects were recruited among CPAP-treated OSA outpatients
followed at the Center for Investigation and Research in Sleep
(Lausanne, Switzerland). Inclusion criteria were >18 years of
age, initial apnea–hypopnea index (AHI) >15/h, good toler-
ance to CPAP, mean use of CPAP of >4 h/night in the last
3months, and residual AHI on CPAP <10/h. Exclusion criteria
were sleep-related disorders other than OSA, any other disor-
der disturbing sleep, use of opiates, benzodiazepines, and mus-
cle relaxants, unstable cardiovascular disease, and inability to
consent.
Design and Set-Up
All participants underwent two supervised full polysomnogra-
phies, one with CPAP only and one with O-PAP. They were
randomized in blocks of four to receive CPAP or O-PAP first.
During the first night, a CPAP titration was performed, starting
in the first NREM2 period, using an initial pressure of 4 cmH2O
and increasing by steps of 1 cmH2O until control of apneas and
hypopneas was achieved. Seventy percent of this optimal pressure
was then applied during both polysomnographies. The titration
time was not included in the analyses.
Pressure oscillations were administered using a custom-made
pressure oscillator connected to the CPAP through a “Y” tub-
ing (Figures 1 and 2). The oscillations’ amplitude was fixed
(1 cmH2O) and the frequency was titrated by the technician while
FIGURE 1 | The O-PAP setting. The pressure oscillation generator (a) and
the CPAP (b) are connected to the patient’s mask through a “Y” tubing (c).
Modified from Wikimedia Commons.
FIGURE 2 | Schematic drawing of O-PAP in a patient with fixed
8cmH2O CPAP: the O-PAP produces 1cmH2O pressure oscillations
(blue line) that are superimposed onto the pressure generated by the
CPAP (red line). PAW, airway pressure.
the patient was awake, starting with 15Hz, until the patient
perceived the vibrations in his throat and not his mouth or thorax.
The polysomnographies were performed using an Embla
N7000™ and analyzed with the Somnologica™ software (Embla
Systems, Inc., Broomfield, CO, USA). One investigator blinded to
treatment modality scored sleep stages according to the American
Academy of SleepMedicine (AASM) 2007 recommendations (10),
and respiratory events using the criteria from the AASM update
published in 2012 (11).
Themain study endpoints were total sleep time, arousals index,
respiratory arousals index, sleep efficiency, and the Leeds sleep
evaluation questionnaire (LSEQ) (12). The secondary endpoints
were the residual AHI under a suboptimal pressure (70% of
the optimal titrated pressure), the AHI according to the body
position and the sleep stages, and the oxygen desaturation index
(ODI)3%.
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Statistics
Sample size was estimated empirically, as there was no data avail-
able on the effect of O-PAP on sleep quality. We estimated that we
needed to include 12 patients to have an 80% power to detect a
difference of 5% in sleep efficiency with a SD of 6% (1  β= 0.8,
α= 0.05). Statistical analysis was made using Medcalc statistical
software (MedCalc Software, 8400, Ostend, Belgium). Results are
reported asmean SD, ormedian interquartile range (IQR). To
compare different outcomes between CPAP and O-PAP, we used
paired t-tests for normally distributed data andWilcoxon tests for
non-normally distributed data.
The studywas approved by the local ethics committee (protocol
296/12) and all patients gave written informed consent.
Results
Fourteen subjects were included in the study. Their character-
istics are shown in Table 1. Seventy-one percent of them were
obese (BMI >30 kg/m2) and all but one had severe OSA (AHI
>30/h). Themedian pressure applied during both nights (~70%of
titrated pressure) was 6.0 [4.3–9.8] cmH2O. The mean oscillation
frequency applied was 27.1 6.9Hz.
Comparison of the respiratory and sleep parameters under both
conditions is shown in Table 2. Sleep quality parameters (arousal
index, respiratory arousals index, sleep time, and sleep efficiency)
and the perceived sleep quality assessed by the LSEQ were not
altered byO-PAP. There was a trend toward a decrease in AHI and
ODI with O-PAP compared to CPAP alone, especially in NREM
sleep and in the supine position, but none of these differences
reached statistical significance.
Discussion
The main finding of this study is that O-PAP is well tolerated
and does not alter objective nor subjective sleep quality in OSA
patients. This suggests that the 1 cmH2O pressure oscillations
applied with O-PAP do not disturb sleep, even when used during
the whole night in OSA patients.
As shown by Plowman et al. (8), pressure oscillations delivered
to the upper airway of dogs can trigger an increase in GG EMG
activity. In a human physiological study, Henke and Sullivan
showed that intermittent pressure oscillations also had a stimu-
lating effect on the upper airway muscle tone (9). It is thus pos-
sible that the constant oscillations generated by the O-PAP could
stimulate GG activity and decrease the CPAP pressure required to
prevent upper airway collapse and improve the patient’s tolerance
to the treatment. Even though our sample was not large enough
to determine the effect of continuous oscillations on the AHI,
we found an interesting trend toward a decrease in the residual
AHI compared to standard CPAP under subtherapeutic pressure.
These preliminary results should stimulate further research on the
effects of O-PAP in OSA patients.
In our study, O-PAP seems to have a greater effect in the supine
position and in NREM sleep but not in non-supine position and
in REM sleep. This may be due to an altered GG responsiveness
since a lower GG activation in response to negative pharyngeal
pressure was previously reported in non-supine positions (13)
TABLE 1 | Patients’ characteristics.
Mean SD
Age (years) 59.9 10.1
BMI (kg/m2) 34.8 7.2
Sex M/F (N) 13/1
Neck circumference (cm) 45.0 4.4
Initial AHI (events/h) 58.7 25.2
CPAP use (years) 4.1 1.8
CPAP pressurea (cmH2O) 12.3 2.9
Type of mask (N/FF) 6/8
aCPAP/CPAP, N 12/2
aFixed pressure or pressure at 95th percentile for aCPAP.
N, nasal; FF, full face; aCPAP, autoadjusted CPAP.
TABLE 2 | Objective and subjective sleep quality parameters and residual
AHI with O-PAP and CPAP under a pressure corresponding to 70% of the
optimal CPAP pressure.
CPAP O-PAP p
Arousal index (/h) 32.5 [23.7–44.4] 28.1 [22.5–34.7] 0.296
Respiratory arousals
index (/h)
16.2 [11.0–21.2] 11.5 [5.4–20.8] 0.104
Sleep timea (min) 356.6 [232.8–390.2] 336.6 [234.5–361.0] 0.325
Sleep efficiency (%) 90.0 [78.0–92.5] 88.1 [71.9–92.6] 0.542
Sleep quality VAS (mm) 78.8 [60.6–85.7] 75.5 [57.4–85.4] 0.695
AHI (/h) 20.5 [13.7–28.9] 14.3 [8.5–25.8] 0.194
AHI supine (/h) 36.9 [24.0–58.4] 23.6 [11.5–66.8] 0.432
AHI non-supine (/h) 11.7 [4.5–16.9] 12.3 [4.4–21.9] 0.966
AHI in REM sleep (/h) 7.9 [5.2–13.6] 12.6 [9.1–26.7] 0.426
AHI in NREM sleep (/h) 22.4 [13.7–30.9] 13.2 [8.2–22.2] 0.104
ODI 3% (/h) 16.2 [9.9–35.6] 12.7 [9.4–22.1] 0.583
aSleep time does not include titration.
REM, rapid eye movement sleep; NREM, non-rapid eye movement sleep; VAS, visual
analog scale.
Maximum score 100mm. Higher score indicates better sleep quality.
Results are expressed as median and interquartile range.
and in REM sleep (14). We can also anticipate that O-PAP could
be more efficient in younger patients with preserved pharyngeal
sensitivity to air vibration since long-term snoring and sleep apnea
are associated with altered pharyngeal sensitivity (15), probably
due to sensitive nerve injuries. To determine whether O-PAP
could allow treating OSA with lower pressures than CPAP, larger
studies including pharyngeal sensitivity measurements and fine
CPAP/O-PAP titrations are required.
Our study has a few limitations. First, due to the easily perceived
O-PAP vibrations, patients or PSG technician blinding was not
feasible. However, the investigator interpreting the polysomno-
graphies was blinded to treatment allocation. Second, our sample
size was small. Finally, because the study was powered to find a
difference in sleep efficiency, it did not have enough power to
detect a significant effect difference between O-PAP and regular
CPAP on AHI.
In conclusion, O-PAP seems to be a safe and well-tolerated
therapy that does not affect subjective nor objective sleep quality.
The positive trend we found toward a reduction in residual AHI
with O-PAP should stimulate further research with larger groups
of patients to better determine if O-PAP could control OSA with
lower pressure than standard CPAP.
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